Form 8-K - Current report:
SEC Accession No. 0001437749-25-013414
Filing Date
2025-04-29
Accepted
2025-04-29 08:35:09
Documents
19
Period of Report
2025-04-29
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250428_8k.htm   iXBRL 8-K 27802
2 EXHIBIT 99.1 ex_808251.htm EX-99.1 15300
3 EXHIBIT 99.2 ex_808252.htm EX-99.2 1248
8 image1.jpg GRAPHIC 233806
9 mbrx20250428_8kimg001.jpg GRAPHIC 5067
10 molelogo.jpg GRAPHIC 17956
  Complete submission text file 0001437749-25-013414.txt   549446

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250429.xsd EX-101.SCH 3580
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250429_def.xml EX-101.DEF 11425
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250429_lab.xml EX-101.LAB 15311
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250429_pre.xml EX-101.PRE 11585
21 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250428_8k_htm.xml XML 2846
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 25882835
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)